Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III.

摘要: Background: Iloprost therapy for severe peripheral obstructive arterial disease (POAD) has demonstrated to be effective in re- ducing the need amputation. However feasibility of a 28-day infusion regimen less stages is poor due lenght hospital stay. A randomized, controlled, parallel-group pilot study was carried out with aim evaluate clinical and circulatory effects Iloprost, sta- ble prostacyclin analogue, administered two different schedules patients POAD at Leriche Fontaine stage III. Methods: Twenty 16 males 4 fe- males, mean age 66 ± 6 years) objective signs POAD, rest pain least weeks posterior tibial artery pressure > 50 mmHg, were randomized either i.v. up 2 ng/Kg/min 6/h/day 28 days (Group A) or 1.5 16/h/day 7 B). At baseline (before starting first infusion) after (for group B only, end therapy) (end Group A, B) following parameters evaluated: walking distance, analgesic consumption, plethysmographyc (first flow, peak flow time) laser Doppler para- meters (rest post ischemic flow). Results: After days, both increased capacity (maxi- mum distance/pain free dis- tance +119/+84% +199/+85% respectively, respectively) reduced (- 45% - 48% respectively consumption im- proved pa- rameters. Tolerability seemed better B, suggesting that lower dose shorter duration period might sult incidence headache thus, principle, increasing patient acceptability. Conclusions: The results this study, if confirmed by larger trials, could have important positive implications terms costs, comfort management.